0000000000162265

AUTHOR

C. Sapienza

showing 4 related works from this author

Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.

2017

Abstract Background Few studies investigated the role of mycophenolate mofetil in inflammatory bowel disease, and none of them had specifically focused on patients with previous multiple intolerances and/or nonresponses to conventional immunosuppressants and biologics. Aims To evaluate clinical benefit and tolerability profile of mycophenolate mofetil in patients with inflammatory bowel disease and limited treatment options. Methods All consecutive patients with previous multiple intolerances and/or nonresponses to immunosuppressants and biologics who started an off-label treatment with mycophenolate mofetil from January 2014 to February 2016 were entered in a prospectively maintained datab…

AdultMalemedicine.medical_specialtyDrug ResistanceKaplan-Meier EstimateMycophenolateInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineIntolerancesInternal medicineMedicineHumansIn patientEnzyme InhibitorsAgedCrohn's diseaseBiological ProductsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisDiscontinuationTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyFemalebusinessImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Psoriasis and Inflammatory Bowel Disease.

2018

<b><i>Background:</i></b> Inflammatory bowel disease (IBD) and psoriasis (PS) are associated conditions. The reason for this association lies in the sharing of predisposition genes and common immunological mechanisms. <b><i>Summary:</i></b> This review will focus on the interplay between IBD and PS, with details on prevalence and phenotype of PS in IBD, genetics, pathogenetic pathways, and therapy. <b><i>Key Messages:</i></b> Microbiome seems relevant in both conditions: a reduction of beneficial bacteria has been observed. IBD and PS have in common some comorbidities like cardiovascular disease, similar risk of cancer …

business.industryGastroenterologyCancerGeneral MedicineDiseasemedicine.diseaseInflammatory Bowel DiseasesPhenotypeInflammatory bowel disease03 medical and health sciences0302 clinical medicinePhenotype030220 oncology & carcinogenesisPsoriasisImmunologyGenetic predispositionmedicinePrevalenceHumansPsoriasis030211 gastroenterology & hepatologyTumor necrosis factor alphaMicrobiomebusinessDigestive diseases (Basel, Switzerland)
researchProduct

The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

2018

Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD. Methods All consecutive patients with loss of response to anti-TNFα monotherapy despite an intensive dose optimization who added an IM from October 2014 to October 2016 were entered into a prospective database. Results Among 630 patients treated with anti-TNFα agents during the study period, 46 (7.3%) added an IM. A total of 31 patie…

AdultMalemedicine.medical_specialtyDatabases FactualCombination therapyGastroenterologyInflammatory bowel diseaseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdalimumabHumansImmunology and AllergyProspective StudiesAdverse effectbiologyTumor Necrosis Factor-alphabusiness.industryRemission InductionC-reactive proteinAdalimumabGastroenterologyAntibodies MonoclonalMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseInfliximabGolimumabInfliximabDiscontinuationC-Reactive ProteinTreatment Outcome030220 oncology & carcinogenesisbiology.proteinDrug Therapy CombinationFemale030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugInflammatory Bowel Diseases
researchProduct

Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience

2017

The occurrence of thiopurine-related adverse events (AEs) may complicate the management of patients with inflammatory bowel disease (IBD). We aimed to evaluate the tolerability of thiopurines in a current IBD setting.All consecutive patients who started a treatment with azathioprine (AZA) from January 2010 to March 2016 were entered in a prospectively maintained database, and the AEs which led to the permanent discontinuation of the drug were reported.Two hundred and fifty three patients were included. Median total follow-up was 32 months (range: 0.2-75 months). At the end of the study, AZA was discontinued in 160 patients (63.2%). The main reason leading to drug withdrawal was the occurren…

AdultMalemedicine.medical_specialtyNauseaAzathioprineKaplan-Meier EstimateInflammatory bowel disease03 medical and health sciencesDrug withdrawal0302 clinical medicineInternal medicineAzathioprinemedicineHumansCumulative incidenceProspective StudiesAdverse effectMercaptopurinebusiness.industryGastroenterologyNauseaMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurgeryDiscontinuationItalyTolerability030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologymedicine.symptombusinessImmunosuppressive Agentsmedicine.drugScandinavian Journal of Gastroenterology
researchProduct